PENNSAID 16 MG / ML SKIN SOLUTION
Topical medications for joint and muscle pain.
1 ml of cutaneous solution contains 16 mg of diclofenac sodium.
Dimethylsulphoxide, ethanol, glycerin, propylene glycol, distilled water.
PENNSAID (16 mg / ml of diclofenac sodium) is a cutaneous solution indicated in the symptomatic relief of pain associated with osteoarthritis of the superficial joints, including the knee. No data are available on the use of PENNSAID in large and deep joints covered with muscle or other soft tissue layers, such as the hip or spine.
CONTRAINDICATIONS / EFF.SECONDAR
PENNSAID (16 mg / ml of diclofenac sodium) is contraindicated: in patients with hypersensitivity to the active substance, to dimethylsulfoxide (DMSO) or to any of the excipients; during pregnancy and breastfeeding; in those subjects in which, after taking oral acetylsalicylic acid (ASA) or other non-steroidal anti-inflammatory drugs (NSAIDs), asthmatic access, urticaria, acute rhinitis or other allergic manifestations have occurred, since there is a sensitivity potential crossed with other NSAIDs, also of different groups.
Posology and method of administration. The drug is applied topically to the painful joint. After washing the part to be treated with water and soap and waiting for it to dry, apply about 20 or 40 drops (about 0,5 or 1 ml) of PENNSAID (16 mg / ml of diclofenac sodium) respectively for a medium joint (e.g. wrist) or large (e.g. knee). Patients should use up to a maximum of 40 drops four times a day per joint as recommended by the attending physician. So that the product does not run away from the area to be treated, apply the solution by dividing it into portions of 5 or 10 drops for a medium or large joint. Distribute the drug evenly over the part to be treated with your hand or fingers. Repeat the procedure until the entire recommended dose of the drug has been applied. Run the application 4 times a day. Renal and hepatic impairment.Patients with renal and hepatic impairment. Pediatric population. The safety and efficacy of the drug in children have not been established. Since no experience has been gained with the drug for pediatric use, use in this group of patients is not recommended. Route of administration. Cutaneous use.
Do not store above 25 degrees C. Do not refrigerate.
The appearance of undesirable effects can be reduced by using laminima effective dose for the shortest time necessary to control symptoms. Elderly, In the elderly there is an increased frequency of adverse reactions to NSAIDs for oral use, especially gastrointestinal bleeding and perforation, which can be fatal. Patients with a history of gastrointestinal toxicity, particularly if elderly, must report any abnormal abdominal symptoms (especially gastrointestinal bleeding) especially in the initial stages of therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic-epidermal necrolysis, have been reported very rarely in association with NSAIDs. In patients the maximum risk of such reactions occurs in the early stages of therapy: the onset of reactions occurs in fact within the first month of therapy in most cases. Therapy should be stopped at the first appearance of rashcutaneous, mucosal lesions or any other sign of hypersensitivity. Patients should be advised to wash their hands after application to avoid contact with the eyes, mucous membranes and the skin not affected by the treatment. No other medicines should be applied to the affected area at the same time as PENNSAID. The possibility that undesirable effects may occur following topical application of the drug is very low when compared to the frequency of occurrence of undesirable effects following administration of diclofenac orally, due to the low systemic absorption of PENNSAID. This medicinal product should be used with caution in patients with impaired renal function as isolated cases of systemic reactions with deterioration of renal function have been observed following oral or topical administration of NSAIDs. The lowest dosage of PENNSAID per joint should be considered. Hepatic system There may be a slight increase in liver function tests following treatment with PENNSAID. If these abnormal values persist or worsen, or if clinical signs or symptoms indicating liver disease arise, or other manifestations arise (e.g. eosinophilia, rash) the administration of the drug must be interrupted. If the need arises to administer this medicinal product in the presence of severe hepatic impairment, this must be done under close medical observation. Use caution when using diclofenac sodium in patients with hepatic porphyria, as diclofenac sodium may trigger a seizure. Gastrointestinal system. Peptic ulcerations, perforations and gastrointestinal bleeding, sometimes severe and rarely fatal, in the presence or absence of preliminary symptoms, have been reported during oral or rectal therapies with nonsteroidal anti-inflammatory drugs (NSAIDs). However, the maximum serum diclofenac level after the topical application of PENNSAID is low (50 times lower than that achieved after the oral administration of 25 mg diclofenac). Therefore, PENNSAID (diclofenac sodium) can be reasonably administered under close medical supervision to patients prone to gastrointestinal irritations, including those with a history of peptic ulcer induced by other non-steroidal anti-inflammatory drugs or suffering from other inflammatory diseases of the gastrointestinal tract (such as ulcerative colitis or Crohn's disease) .In such cases, the physician should evaluate the benefits of treatment against the possible risks. The patient should be instructed to contact their doctor immediately at the first signs or symptoms of gastric ulcer or gastrointestinal bleeding. Such reactions can occur at any time during treatment, without symptoms or preliminary signs. Dermatology. The part treated with the drug must not be covered by occlusive bandages. The drug should be applied to the skin without injury or infection. Do not use the drug on joint surfaces with previous skin diseases (e.g. psoriasis) unless advised by your doctor. The application of the drug on the mucous membranes is not recommended. Hypersensitivity '. The dimethylsulphoxide (DMSO) contained in this drug can induce the release of histamine and hypersensitivity reactions have also been reported occasionally after topical administration. In the presence of any anaphylactoid reactions it is necessary to institute adequate therapy and stop the application of the drug. Ophthalmology. Neglistudi on animals, high doses, especially orally, of DMSO have caused abnormal changes in the lens of the eye. In primate and human studies, such changes were not observed after ocular and oral administrations of dimethylsulfoxide. Infections The anti-inflammatory and analgesic effects of diclofenac sodium can mask the usual signs of infection. Therefore, the doctor must pay particular attention to the possible development of skin infections located in the area on which the patient has applied the drug. It has been found that the maximum concentration of diclofenac in the blood, after the application of the maximum dose of PENNSAID (1ml ), is less than 10 ng / ml. This value is 50 times lower than the maximum concentration of diclofenac in the blood after oral administration of 25 mg didiclofenac.
The interactions reported in this section have been observed after the systemic administration of diclofenac sodium. The risk associated with the topical use of PENNSAID is not known, but it is probably of low entity. Acetylsalicylic acid (ASA). Didiclofenac serum levels may decrease when taken simultaneously with acetylsalicylic acid. The bioavailability of acetylsalicylic acid is reduced by the presence of diclofenac. Although such pharmacokinetic interactions do not appear to be clinically relevant, there is no established benefit in the concomitant use of these two drugs. Digoxin: Diclofenac can increase the concentration of digoxin in plasma. Dose modifications may therefore be necessary. Lithium. Plasma lithium concentrations may increase if administered concurrently with diclofenac (which impairs renal clearance of lithium). It may be necessary to adjust the lithium dosage. Oral hypoglycemic drugs. Pharmacodynamic studies have shown no potentiation of effects due to concomitant administration with diclofenac; however, isolated cases of both hypoglycaemic and hyperglycemic effects on the dosage of hypoglycaemic drugs have been reported. Anticoagulants. NSAIDs can increase the effects of anticoagulants, such as warfarin. Diuretics. Nonsteroidal anti-inflammatory drugs are known to inhibit the activity of diuretics. The concomitant intake of anti-inflammatory and potassium-sparing diuretics can cause an increase in serum dipotassium, and therefore periodic monitoring of blood / plasma levels is necessary. Glucocorticoids. Co-administration may aggravate side effects in the gastrointestinal tract. Nonsteroidal anti-inflammatory drugs (NSAIDs) The simultaneous oral administration of two or more non-steroidal anti-inflammatory drugs can promote the appearance of undesirable effects (see Special warnings and precautions for use). Methotrexate. The administration of non-steroidal anti-inflammatory drugs less than 24 hours before or after treatment with methotrexate should be done with caution, since these drugs can increase their blood concentration and increase their toxicity. Cyclosporine. The nephrotoxicity of cyclosporine may be increased due to the effects of nonsteroidal anti-inflammatory drugs on renal prostaglandin. Quinolone antibacterials: Isolated cases of seizures have been reported, which may have been due to the concomitant use of quinolones and nonsteroidal anti-inflammatory drugs. Antihypertensive drugs: As with other nonsteroidal inflammatory drugs, diclofenac can reduce the antihypertensive effects of propranolol, other beta blockers and other antihypertensive drugs. Other medicines. Diclofenac sodium salt must not be used together with diclofenac potassium salt, since both are present in the plasma in the form of the same active organic ion. Corticosteroids: increased risk of gastrointestinal ulcerations or bleeding.
The undesirable effects are divided into those which manifest themselves in the application site and those which manifest themselves as a systemic effect. Topical application. Six double-blind controlled clinical trials revealed the following side effects with a significant increase in incidence in the PENNSAID-treated group compared to the placebo-treated comparison group. At the application site, cases of dry skin (35,80% versus 6,86% in the placebo group) and rash (10,44% versus 2,86% in the placebo group) were statistically significant. Other side effects of PENNSAID, which were statistically significant compared to placebo, are constipation (3,83% versus 0,57%), dyspepsia (8,98% versus 4%) and flatulence (4,49% versus 0,57). %). Photoallergic reactions and contact dermatitis have been reported after the topical application of diclofenac. The systemic absorption of diclofenac sodium after topical application of PENNSAID is very low compared to that of taking diclofenac sodium tablets. However, when PENNSAID is applied to a relatively large area of the skin for a prolonged period of time, the possibility of systemic side effects similar to the systemic effects caused by diclofenac (see below) by mouth cannot be completely excluded. Possible systemic side effects are described below. Oral administration: Oral administration of diclofenac causes adverse events due to gastrointestinal reactions both systemically and locally. The most serious gastrointestinal adverse events are ulcerations and bleeding, while the most serious, although rare, dermatological reactions are represented by erythema multiforme (Stevens-Johnson and Lyell syndromes). Occasional deaths have been reported, especially in the elderly. Bullous reactions including Stevens Johnson Syndrome and Toxic Epidermal Necrolysis (very rare) Edema, hypertension and heart failure have been reported in association with NSAID treatment. Adverse events are categorized by frequency as follows: very common (> = 1/10), common (> = 1/100, <1/10), uncommon (> = 1 / 1.000, <1/100) , rare (> = 1 / 10.000, <1 / 1,000) and very rare (<1 / 10.000), not known (frequency cannot be estimated from the available data) Gastrointestinal disorders Uncommon: epigastric, gastric or abdominal, abdominal cramps, nausea, dyspepsia, anorexia, diarrhea, vomiting and flatulence; rare: gastrointestinal bleeding (bloody diarrhea, melaena, haematemesis) gastric and intestinal ulcerations with or without bleeding or perforation; not known: diseases of the large intestine (for example: non-specific hemorrhagic colitis and aggravation of ulcerative colitis or Crohn's disease), intestinal diaphragmatic constrictions, hyperacidity, stomatitis, glossitis, sticky tongue, lesions of the esophagus, constipation and pancreatitis , taste disturbances. Nervous system disease. Uncommon: dizziness, headache and dizziness; rare: drowsiness, malaise, concentration disturbances and tiredness; note: sensory disturbances including paraesthesia, memory disturbances, disorientation, insomnia, irritability, convulsions, depression, anxiety, nightmares, tremors, psychotic reactions and aseptic meningitis. Eye disorders. Not known: visual disturbance (blurred vision, diplopia) Ear and labyrinth disorders. Not known: hearing impairment, tinnitus. Cardiac pathologies. Rare: palpitations, angina and arrhythmia; not known: aggravation of heart failure and hypertension. Vascular pathologies. Not known: vasculitis. Pathology of skin and subcutaneous tissue. Uncommon: itchy rashes; rare: urticaria; not known: bullous dermatosis, erythema, eczema, erythema multiforme, Stevens-Johnson syndrome, Lyell syndrome (toxic epidermal necrolysis), erythroderma (exfoliating dermatitis), hair loss, photosensitivity reactions and purpura, which include allergic purpura, burning sensation when applying, dry skin. Renal and urinary disorders. Rare: edema (facial, generalized, peripheral); not known: acute renal failure, nephrotic syndrome, urinary abnormalities (e.g. hematuria and proteinuria), interstitial nephritis and papillary necrosis. Blood and lymphatic system disorders. Not known: thrombocytopenia, leukopenia, agranulocytosis, hemolytic anemia, aplastic anemia and anemia due to gastrointestinal bleeding. Hepatobiliary pathologies. Uncommon: increases (> = 3 times above the normal limit) in AST, ALT; rare: abnormal liver function including hepatitis with or without jaundice; not known: fulminant hepatitis. Respiratory, thoracic and mediastinal disorders. Rare: hypersensitivity reactions such as asthma in patients sensitive to acetylsalicylic acid, e.g. bronchospasm; systemic anaphylactic / anaphylactoid reactions, including hypotension; not known: pneumonia. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk balance of the medicinal product.
PREGNANCY AND BREASTFEEDING
Pregnancy: the drug is contraindicated during pregnancy. Breastfeeding: the drug is contraindicated during breastfeeding.
Delivery is made within 24-72 working hours, Monday to Friday, excluding holidays.
WARNING! In times of high turnout, such as Black Friday, Christmas or Sales, delivery times may increase.
Shipping costs are calculated automatically during the order phase.
- EXPRESS shipping 24-72 working hours
For orders over € 40,00 shipping is free. For orders below € 40,00 the following applies:
- - € 0,00 - € 9,99: € 6,99
- - € 10,00 - € 19,99: € 5,99
- - € 20,00 - € 29,99: € 4,99
- - € 30,00 - € 39,99: € 3,99
- - € 40,00 and up: € 0,00
- Cash on delivery
For orders over € 70,00 shipping is € 3.99. For orders below € 70,00 the following applies:
- - € 0,00 - € 9,99: € 10,98
- - € 10,00 - € 19,99: € 9,98
- - € 20,00 - € 29,99: € 8,98
- - € 30,00 - € 39,99: € 7,98
- - € 40,00 - € 49,99: € 6,98
- - € 50,00 - € 59,99: € 5,98
- - € 60,00 - € 69,99: € 4,98
- - € 70,00 and up: € 3,99
WARNING! If you want to pay cash on delivery, you must select the item twice when ordering, otherwise € 3,99 will be added to the total amount for the service.
- Delivery within 12.00 TNT Express
By placing the order by 12:30 on the current day, delivery will take place by 12.00 on the following day, excluding Saturdays and Sundays.
- € 10.99
- Delivery within 10.00 TNT Express
By placing the order by 12:30 on the current day, delivery will take place by 10.00 on the following day, excluding Saturdays and Sundays.
- € 15.99
- € 7.98
Farmaveloce will deliver your order to the address of your choice throughout Italy, including the islands.
All orders with EXPRESS shipping are entrusted to the courier BRT, GLS, UPS, DHL, FedEx & TNT, Poste Italiane.
farmaveloce.com collects some Personal Data from its Users.
Owner of the Data Privacy
Via Savelli, 10 35129 Padua (Italy)
Email address of the owner: ROAD@ farmaveloce.com
The site: farmaveloce.com
Types of data collected
Among the Personal Data collected, independently or through third parties, there are: Cookies, Data of
use, name, surname, telephone number, VAT number, address, country, postcode, various types
of data, city and tax code.
Full details on each type of data collected are provided in the dedicated sections of this
Personal Data can be freely provided by the User or, in the case of Usage Data,
collected automatically when using the site.
Unless otherwise specified, all data requested by the site are mandatory.
If the User refuses to communicate them, it may be impossible for farmaveloce.com to provide the Service.
In cases where farmaveloce.com indicates some Data as optional, Users are free to
refrain from communicating such Data, without this having any consequence on the availability of the
Service or its operation.
Users who have doubts about which data are mandatory are encouraged to contact
of third party services used by the site, unless otherwise specified, has the purpose of providing the Service
requested by the User, in addition to the additional purposes described in this document and in the Cookie
Policy, if available.
The User assumes responsibility for the Personal Data of third parties obtained, published or shared
through farmaveloce.com and guarantees to have the right to communicate or disseminate them, freeing
the Owner from any liability to third parties.
Mode and place of processing of data collected
Mode of treatment
The Data Controller adopts the appropriate security measures to prevent access, disclosure, the
unauthorized modification or destruction of Personal Data.
The treatment is carried out using IT and / or telematic tools, with methods
organizational and with logic strictly related to the purposes indicated. In addition to the owner, in some
cases, other subjects involved in the organization of the site (staff
administrative, commercial, marketing, legal, system administrators) or external subjects
(such as third party technical service providers, couriers, hosting providers, IT companies,
communication agencies) also appointed, if necessary, Data Processors by the
Holder. The updated list of Managers can always be requested from the Data Controller
Legal basis of the processing
The Holder processes Personal Data relating to the User in the event one of the following conditions exists:
• the User has given consent for one or more specific purposes; Note: in some systems
the Data Controller can be authorized to process Personal Data without the existence of the
User's consent or another of the legal bases specified below, until
the User does not object ("opt-out") to this treatment. This however is not applicable if
the processing of Personal Data is regulated by European legislation on
protection of personal data;
• processing is necessary for the execution of a contract with the User and / or for the execution of
• processing is necessary to fulfill a legal obligation to which the Data Controller is subject;
• processing is necessary for the performance of a public interest task or for
the exercise of public powers with which the Data Controller is invested;
• the processing is necessary for the pursuit of the legitimate interest of the owner or third parties.
In any case, it is always possible to request the Data Controller to clarify the concrete legal basis of each
treatment and in particular to specify whether the treatment is based on the law, provided for by a
contract or necessary to conclude a contract.
The data are processed at the owner's operating offices and in any other place where the parties involved
in the treatment are localized.
For more information, contact the owner.
The User's Personal Data may be transferred to a country other than the one in which the User
is situated. To obtain further information on the place of treatment, the User can refer to
to the section on details on the processing of Personal Data.
The User has the right to obtain information regarding the legal basis for the transfer of Data to
outside the European Union or to an international international law organization
public or consisting of two or more countries, such as the UN, as well as on the measures of
security adopted by the Data Controller to protect the Data.
The User can check whether one of the transfers described above takes place by examining the section
of this document relating to details on the processing of Personal Data or request information from the
Owner by contacting him at the ends shown at the beginning.
The Data are processed and stored for the time required by the purposes for which they were collected.
• Personal Data collected for purposes related to the execution of a contract between the Owner and
the User will be held until the execution of this contract is completed.
• Personal Data collected for purposes related to the legitimate interest of the Owner will be
held until the satisfaction of this interest. The User can get further
information on the legitimate interest pursued by the Data Controller in the relevant sections of
this document or by contacting the owner.
When the treatment is based on the User's consent, the Data Controller can keep Personal Data
longer until such consent is revoked. In addition, the owner could be
obliged to keep Personal Data for a longer period in compliance with an obligation to
law or by order of an authority.
At the end of the retention period, Personal Data will be deleted. Therefore, at the expiration of
this term the right of access, cancellation, rectification and the right to data portability
they can no longer be exercised.
The use of the data collected
User data are collected to allow the owner to provide their services, as well as for
following purposes: Statistics, Interaction with external social networks and platforms, Access to
account on third party services and Contact the User.
To obtain further detailed information on the purposes of the processing and on Personal Data
concretely relevant for each purpose, the User can refer to the relevant sections of
Facebook permissions requested by la farmaveloce.com
Unless otherwise specified
The site may request some Facebook permissions that allow it to perform actions with the account
User's Facebook and to collect information, including Personal Data, from it. This service
allows the site to connect with the User's account on the Facebook social network, provided by
For more information on the following permissions, refer to the documentation of the
The required permits are as follows:
The basic information of the User registered on Facebook which normally includes the following
Data: id, name, image, gender and localization language and, in some cases, the "Friends" of
Facebook. If the User has made publicly available additional data, the same will be available.
Access to private data
Allows access to the User's and friends' private data.
Access to friend lists
Provides access to the lists of friends that the User has created.
Add or edit photos.
Allows the app to add or edit User videos.
Provides access to the list of events in which the User participates.
I like it
Provides access to the list of all the pages that the User has marked with the Like.
Provides access to the User's website.
Details on the processing of Personal Data
The Personal Data are collected for the following purposes and using the following services:
Access to accounts on third party services
This type of service allows the site to collect data from your accounts on third party services and
perform actions with them.
These services are not activated automatically, but require express authorization
Access to the Facebook account (farmaveloce.com)
This service allows the site to connect with the User's account on the social network
Facebook, provided by Facebook, Inc.
Permissions asked: Access to private data, Access to friend lists, Upload photos, Upload of
Videos, Events, Likes and Website.
Contact the user
By filling in the contact form with their Data, the User consents to their use for
respond to requests for information, quotes, or any other kind indicated
from the form header.
Personal data collected: post code, city, tax code, surname, address, country, name, number of
telephone, VAT number and various types of data.
Interaction with external social networks and platforms
This type of service allows you to interact with social networks, or with other platforms
external, directly from the pages of the site
The interactions and information acquired from the site are in any case subject to the settings
User privacy related to each social network.
In the event that an interaction service with social networks is installed, it is possible that, too
if Users do not use the service, it collects traffic data relating to the pages in
which it is installed on.
Like button and social widgets for Facebook (Facebook, Inc.)
The "Like" button and Facebook social widgets are social interaction services
Facebook network, provided by Facebook, Inc.
Personal Data collected: Cookies and Usage Data.
The services contained in this section allow the Data Controller to monitor and
analyze traffic data and are used to keep track of User behavior.
Google Analytics (Google Inc.)
Google Analytics is a web analysis service provided by Google Inc. ("Google"). Google uses i
Personal data collected for the purpose of tracking and examining the use of farmaveloce.com,
compile reports and share them with other services developed by Google.
Google may use the Personal Data to contextualise and personalize the advertisements of the
own advertising network.
Personal Data collected: Cookies and Usage Data.
More information on Personal Data
Selling goods and services online
The Personal Data collected is used for the provision of services to the User or for the sale of
products, including payment and possible delivery. Personal Data collected to perfect the
payment may be those relating to the credit card, the current account used for the
bank transfer or other expected payment instruments. Payment data collected by
farmaveloce.com depend on the payment system used.
Users may exercise certain rights with reference to the Data processed by the Data Controller.
In particular, the User has the right to:
• withdraw consent at any time. The User can withdraw consent to the treatment
of their Personal Data previously expressed.
• object to the processing of their data. The user can object to the processing of their data
when it occurs on a legal basis other than consent. Further details on the law
of opposition are indicated in the section below.
• access their Data. The User has the right to obtain information on the Data processed by the
Holder, on certain aspects of the treatment and to receive a copy of the Data processed.
• verify and request correction. The User can verify the correctness of their Data
and request its updating or correction.
• obtain the limitation of the treatment. When certain conditions are met,
the User can request the limitation of the processing of their Data. In this case the Owner
will not process the Data for any other purpose other than their conservation.
• obtain the cancellation or removal of their Personal Data. When they recur
certain conditions, the User can request the deletion of their Data by the
• receive your data or have it transferred to another holder. The User has the right to receive i
own Data in structured format, commonly used and readable by automatic device and, where
technically feasible, to obtain the transfer without hindrance to another owner. This
provision is applicable when the Data are processed with automated tools and the
processing is based on the User's consent, on a contract of which the User is a party or on
contractual measures connected to it.
• propose a complaint. The User can lodge a complaint with the supervisory authority of the
protection of personal data competent or to act in court.
Details on the right of opposition
When Personal Data are processed in the public interest, in the exercise of public powers referred to
the Owner is invested or to pursue a legitimate interest of the Owner, the Users have
right to object to processing for reasons related to their particular situation.
Users are reminded that if their data were processed for direct marketing purposes,
can oppose the treatment without giving any reason. To find out if the owner deals
data for direct marketing purposes Users can refer to the respective sections of
How to exercise the rights
To exercise the User's rights, Users can address a request to the ends of
contact of the Owner indicated in this document. Requests are filed free of charge and
processed by the Owner as soon as possible, in any case within a month.
Additional information on treatment
Defense in court
The User's Personal Data may be used by the Owner in court or in stages
preparatory to its possible establishment for the defense against abuse in the use of
farmaveloce.com or related Services by the User.
The User declares to be aware that the Data Controller may be obliged to reveal the Data
by order of the public authorities.
farmaveloce.com could provide the User with additional and contextual information
concerning specific Services, or the collection and processing of Personal Data.
Log System and Maintenance
For needs related to the operation and maintenance of the site and any third party services from
it used could collect system logs, that is files that record the interactions and that
they may also contain Personal Data, such as the User IP address.
Information not contained in this Policy
Further information in relation to the processing of Personal Data may be requested in
at any time to the Data Controller using the contact details.
Response to "Do Not Track" requests
The site does not support "Do Not Track" requests.
To find out if any third-party services used support them, the User is invited to
consult the respective privacy policies.
any time giving information to Users on this page and, if possible, on the site
as well as, if technically and legally feasible, by sending a notification to Users through one
of the contact details held by the Owner. Therefore, please consult regularly
this page, referring to the date of last modification indicated at the bottom.
If the changes affect treatments whose legal basis is consent, the Owner
will collect the User's consent again, if necessary.
Definitions and legal references
Personal Data (or Data)
It constitutes personal data any information that, directly or indirectly, also in
link with any other information, including an identification number
personal, makes a natural person identified or identifiable.
Data of Use
This is the information collected automatically through the site (also by party applications
third parties integrated into the site), including: IP addresses or domain names of the computers used
by the User who connects with the site, the addresses in URI (Uniform Resource Identifier) notation,
the time of the request, the method used to forward the request to the server, the file size
obtained in response, the numeric code indicating the status of the response from the server (successful, error,
etc.) the country of origin, the characteristics of the browser and operating system used by the
visitor, the various temporal connotations of the visit (for example the time spent on
each page) and the details of the itinerary followed within the Application, with
particular reference to the sequence of the pages consulted, to the parameters relating to the system
operating environment and the IT environment of the User.
The individual who uses the site which, unless otherwise specified, coincides with the interested party.
The natural person to whom the Personal Data refers.
Data Processor (or Manager)
The natural person, legal entity, public administration and any other entity that processes data
Data Controller (or Owner)
The natural or legal person, public authority, service or other body which, individually or
together with others, it determines the purposes and means of the processing of personal data and the tools
adopted, including the security measures relating to the operation and use of
farmaveloce.com. Unless otherwise specified, the Data Controller is the
owner of farmaveloce.com.
farmaveloce.com (or this Application)
The hardware or software tool through which the Personal Data of the
The service provided by the site as defined in the relative terms (if any) on this
site / application.
European Union (or EU)
Unless otherwise specified, any reference to the European Union contained in this
document is intended to be extended to all current member states of the European Union and Space
Small portion of data stored in the User's device.
This privacy statement is drawn up on the basis of multiple legislative systems, including articles 13 and 14 of the Regulation (EU) 2016 / 679.
Unless otherwise specified, this privacy statement only concerns the site.
RIGHT OF WITHDRAWAL
Deadline for withdrawal
The Consumer has a period of fourteen days to withdraw from the contract without having to provide any reason.
The aforementioned term starts:
a) if a service is offered from the day of the conclusion of the contract
b) in the case of sale of a product, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the goods or:
• in the case of multiple goods ordered by the Consumer through a single order and delivered separately, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the last good;
• in the case of delivery of an asset consisting of lots or multiple pieces, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the last lot or piece;
• in the case of contracts for the periodic delivery of goods during a certain period of time, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the first asset.
Obligations of the pharmacy The pharmacy, following the withdrawal of the consumer:
<br>• immediately communicates to the Consumer a confirmation of receipt, on a durable medium, of the Withdrawal exercised;
• reimburses the same all payments received, not including delivery costs, without undue delay and in any case within fourteen days from the day of the communication of the Right of Withdrawal.
• the pharmacy reimburses using the same payment method used by the consumer, unless otherwise agreed after payment.
Obligations for the Consumer
The shipping costs for the return of the products received must be paid by the Consumer, which must be shipped within fourteen days from the date on which he communicated his decision to withdraw from the contract (the deadline is respected if the Consumer returns the goods before the expiry of the fourteen day period).
The substantial integrity of the asset is an essential condition for exercising the right of withdrawal. The Product must therefore be kept with normal diligence and returned intact, complete in all its parts, fully functional and free of signs of wear or dirt.
Exceptions to the Right of Withdrawal - products for which the application of the Right of Withdrawal is excluded
The right of withdrawal cannot be exercised:
a) in case of purchase of medicines and medical devices
b) supply of food, drinks or other goods intended for current consumption in the family and physically supplied by a professional in frequent and regular rounds to the consumer's home, residence or workplace
c) in the case of purchases of less than 50 euros (unless the total consideration that the Consumer must pay regardless of the amount of the individual contracts exceeds 50 euros);
d) in the case of a contract for a service after the complete provision of the service if the execution of the contract began with the express agreement of the Consumer;
e) in case of supply of goods made to measure or clearly personalized;
f) in the event of the supply of goods which are liable to deteriorate or expire rapidly;
g) in the case of the supply of sealed goods that do not lend themselves to be returned for reasons of hygiene or connected to the protection of health and have been opened after delivery;
h) in case of supply of goods which after delivery are by their nature inseparably mixed with other ben.
In the event of a lack of conformity, or delivery of goods that present defects or defects or are different from that provided in the sales contract, i.e. unsuitable for the use for which a good of the same is usually used
type, which differs from the description published on the site or which does not manifest the promised qualities, the provisions of the Legal Guarantee as per articles 128 and following of Legislative Decree 205/2006 (Consumer Code).
Any breakdowns or malfunctions caused by accidental events or by Customer's liability or by a use of the product not in accordance with its intended use and / or as foreseen in the technical documentation attached to the product are excluded from the scope of the Legal Guarantee.
The pharmacy is responsible when the lack of conformity occurs within two years from the delivery of the goods, unless a conventional guarantee is provided after this deadline. In the case of the sale of used goods, the guarantee referred to in the previous paragraph may be limited to a period of time in any case
not less than one year.
The Consumer is obliged to report the defect or defect to me quickly within two months of discovery (unless the sector has recognized or concealed the existence of the defect).
It is assumed that the defects of conformity that occur within six months of delivery of the goods already existed on that date, unless this hypothesis is incompatible with the nature of the asset or with the nature of the defect of
The direct action to assert defects not maliciously concealed by the seller is prescribed within twenty-six months from the delivery of the goods (the Consumer who is agreed for the execution of the contract can nevertheless always assert the rights referred to in this article provided that the lack of conformity has been reported within two months of discovery and before the expiry of the two years from delivery).
In the event of a lack of conformity, the Consumer can request, at no cost (including shipping), the restoration by repair or replacement, at his choice, unless the remedy is objectively impossible or excessively expensive compared to the other.
The above remedy is to be considered excessively expensive if it imposes unreasonable costs on the store compared to the other, taking into account:
a) the value that the asset would have if there were no lack of conformity;
b) the extent of the lack of conformity;
c) the possibility that the alternative remedy can be tried without significant inconvenience for the Consumer.
Repairs or replacements will be carried out within a reasonable time from the request and must not cause significant inconvenience to the Consumer, taking into account the nature of the goods and the purpose for which it was purchased.
The Consumer can request, at his choice, an appropriate price reduction or the termination of the contract if one of the following situations occurs:
a) repair and replacement are impossible or excessively expensive;
b) the seller did not replace within a reasonable time;
c) the replacement or repair previously carried out has caused significant inconvenience to the Consumer.
The use of the asset is taken into account when determining the amount of the reduction or the amount to be returned.
After reporting the lack of conformity, the seller can offer the consumer any other available remedy, with the following effects:
a) if the Consumer has already requested a specific remedy, the seller remains obliged to implement it, with the necessary consequences regarding the commencement of the appropriate term for repairs or replacements, unless the Consumer accepts the proposed alternative remedy;
b) if the Consumer has not already requested a specific remedy, the Consumer must accept the proposal or reject it by choosing another remedy pursuant to this article.
A slight lack of conformity, for which it has not been possible or is excessively burdensome to carry out the remedies of repair or replacement, does not give the right to terminate the contract.
The Legal Guarantee is limited to purchases made by Consumers. As regards subjects other than Consumers, the provisions of the Consumer Code apply to Articles 1490 et seq.
Conventional Manufacturer Warranty
The products sold on the Site may, depending on their nature, be covered by a conventional warranty issued by the manufacturer ("Conventional Warranty"). The customer can only enforce this guarantee against the manufacturer. The duration, the extension, also territorial, the conditions and methods of use, the types of damage / defects covered and any limitations of the Conventional Warranty depend on the individual manufacturer and are indicated in the so-called warranty certificate contained in the product packaging. The Conventional Guarantee is voluntary in nature and does not add, replace, limit or prejudice or exclude the Legal Guarantee.
Payment and security
Your payment information is processed securely. We do not store credit card details nor do we have access to your credit card information.